No type I, III or IV endoleaks, graft migration or adverse events with Incraft at two years


Data from the INNOVATION study presented at the Leipzig Interventional Course (LINC) in Germany continue to demonstrate that the Incraft endovascular aortic repair (EVAR) system from Cordis performs well in patients suffering from abdominal aortic aneurysms two years after treatment. The results were presented on 28 January 2014.

“These positive results are encouraging and build on the favourable short- and mid-term outcomes of the Incraft system observed in the recently published one-year results of the INNOVATION trial,” said Gioachino Coppi, Department of Vascular Surgery at the University of Modena, Italy. “In light of these results and the unique low-profile configuration of the device, Cordis’ Incraft system has the potential to be a valuable alternative to current devices on the market. The system is designed to offer increased applicability in the broad spectrum of anatomical sizes encountered in patients undergoing endovascular aneurysm repair.”

The INNOVATION trial is a multicentre, open-label, prospective study designed to assess the safety and performance of the device in the treatment of patients with abdominal aortic aneurysms with investigational sites in Germany and Italy. Study investigator Giovanni Torsello, University Hospital Münster in Germany presented the two-year results of the INNOVATION study at LINC. At two years, there were no incidences of aneurysm enlargement, endoleaks (type I, III or IV), device or procedure related major adverse events, stent graft migrations or stent fractures. One patient in the study developed a late graft occlusion unrelated to the device that was caused by shrinkage of the aneurysm.

“We are very pleased with these excellent longer term results and look forward to making our Incraft system available to clinicians in need of alternative therapeutic options for patients suffering from abdominal aortic aneurysms,” said Celine Martin, Worldwide President, Cordis Corporation. “The Incraft system was designed to address some of the limitations of current abdominal aortic aneurysm stent grafts and to increase access to this life-saving therapy to a broader range of patients including those with small or diseased vasculature.”

The Incraft system is an endovascular stent graft used in the treatment of abdominal aortic aneurysms featuring an integrated delivery system with an ultra-low profile equivalent to that of a regular 13 French catheter sheath introducer. Most traditional EVAR stent grafts have a system profile ranging from 16 to 22 French in size. This ultra-low profile device is designed for proximal and distal placement accuracy and can be customized during the procedure. The Incraft system provides broad anatomical coverage with a minimal number of product codes to support ease of procedural planning.

The Incraft system is approved for investigational device use only and it not for sale anywhere in the world. The device is currently being investigated in a global pivotal clinical study in the USA and Japan called the INSPIRATION trial, which completed enrolment in August 2013. One-year follow-up data from the trial will support a premarket approval application to the US FDA and a Shonin application in Japan.